AzTrials
AzTrials

Complex Aortic AneurysmsENVISIONNCT07480395

Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.

An observational study of Complex Aortic Aneurysms and Thoracoabdominal Aneurysm, run by W.L.Gore & Associates at 26 sites in 10 countries.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

The registry population consists of patients presenting with complex aortic pathologies amenable to endovascular aortic repair that requires the incorporation of bridging stents to maintain visceral artery perfusion Read more about this study

Who is it for?
Ages 18 years and older
How many people
400 participants
Where
26 sitesin 10 countries
Study dates
Dec 2026to Dec 2035
How long will I take part?
5 Years
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The registry population consists of patients presenting with complex aortic pathologies amenable to endovascular aortic repair that requires the incorporation of bridging stents to maintain visceral artery perfusion. Patients are eligible to participate in the registry if at least one BXB device is intended to be incorporated (first proximal, connected with aortic main body) to maintain visceral artery perfusion. There are no selection criteria (i.e., inclusion or exclusion criteria) based on main aortic body device used, and to allow better RWD representation of the patient population treated with different aortic component, a cap per main aortic body device has been set.

Who may be able to join

  • Informed Consent Form (ICF) is signed by Subject.
  • Age ≥ 18 years at time of informed consent signature.
  • Patient presents with thoracoabdominal, pararenal, juxtarenal, or short-neck infrarenal aortic pathology suitable for endovascular repair.
  • Patient requires the incorporation of ≥ 1 visceral artery and is suitable for use of at least 1 GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (BXB) as a bridging stent (Note: Up to six (6) visceral arteries may be incorporated).
  • Patient is willing to adhere to the institutional standard of care follow-up.

Who cannot join

  • Patient has a prior visceral artery stenting not associated with registry procedure.
  • Patient treated for acute or sub-acute dissection, <90 days from onset of symptoms
  • Patient is intended to be treated with a parallel grafting (e.g., chimney, periscope, sandwich) or octopus technique.
  • Known hypersensitivity to heparin or a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II.
  • Patient has known coagulation disorders including hypercoagulability that are not amenable to treatment.
  • Patient has a life expectancy < 1-year.
  • Patient is participating in an investigational study which may confound registry results, unless approved by Gore

Trial locations and contacts

26 sites in 10 countries. Contact the study team or a site near you to ask about taking part.

26 sites in 10 countries

Germany5 sites
  • Universitäts-Herzzentrum Bad Krozingen

    Bad Krozingen

  • University Medical Center Hamburg-Eppendorf

    Hamburg

  • University of Heidelberg

    Heidelberg

  • Helios Hospital München West

    München

  • LMU Klinikum Campus Großhadern

    München

Other trials in Germany

Italy5 sites
  • Policlinico di Sant'Orsola

    Bologna

  • ASST Spedali Civili di Brescia

    Brescia

  • Arcispedale Sant'Anna

    Ferrara

  • AOU Padova

    Padova

  • AOU Policlinico Umberto I

    Roma

Other trials in Italy

United Kingdom3 sites
  • University Hospital Birmingham

    Birmingham

  • St Thomas Hospital

    London

  • Manchester Royal Infirmary

    Manchester

Other trials in United Kingdom

Austria2 sites
  • Medical University Innsbruck

    Innsbruck

  • Medizinische Universität Wien

    Vienna

Other trials in Austria

Greece2 sites
  • Laiko General Hospital of Athens

    Athens

  • Larissa University Hospital

    Larissa

Other trials in Greece

Netherlands2 sites
  • Amsterdam UMC

    Amsterdam

  • Elisabeth-Tweesteden Hospital

    Tilburg

Other trials in Netherlands

Spain2 sites
  • Complejo Hospitalario Universitario de La Coruña

    A Coruña

  • Hospital Clinico San Carlos

    Madrid

Other trials in Spain

Sweden2 sites
  • Skåne University Hospital

    Malmö

  • Karolinska University Hospital

    Stockholm

Other trials in Sweden

Switzerland2 sites
  • University Hospital Basel

    Basel

  • University Hospital Bern

    Bern

Other trials in Switzerland

Denmark1 site
  • Rigshospitalet University Hospital

    Copenhagen

Other trials in Denmark

About this study

Official title: The ENVISION Registry: REal-World Data CollectioN of GORE deVIceS Used In the endOvascular treatmeNt of Aortic Aneurysms Which Incorporate Visceral Arteries.

The registry population consists of patients presenting with complex aortic pathologies amenable to endovascular aortic repair that requires the incorporation of bridging stents to maintain visceral artery perfusion

Read the detailed description

Patients are eligible to participate in the registry if at least one BXB device is intended to be incorporated (first proximal, connected with aortic main body) to maintain visceral artery perfusion. There are no selection criteria (i.e., inclusion or exclusion criteria) based on main aortic body device used, and to allow better RWD representation of the patient population treated with different aortic component, a cap per main aortic body device has been set

Keywords
FEVAR, BEVAR, TAAA, AAA, Visceral, aortic aneurysm, PMEGs
Medical subject headings
Aortic Aneurysm

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07480395
Study groupRoleWhat they receive
FEVARPatients who are treated with aortic endografts designed exclusively with fenestrations for incorporation of the visceral arteries with at least one BXB device implanted
BEVARPatients who are treated with aortic endografts designed exclusively with directional branches for incorporation of the visceral arteries with at least one BXB device implanted
OTHERPatients who are treated with other endovascular techniques who required incorporation of BXB as bridging stent (i.e. PMEGs).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Freedom from Target Vessel Instability

    Freedom from any death or rupture related to side branch complication (e.g., endoleaks, rupture); any branch occlusion; or any secondary intervention indicated to treat a branch-related complication, including endoleaks, disconnection, kink, stenosis, occlusion, or rupture

    Measured: through 1 year Follow-up

Secondary outcomes (12)
  1. Target Vessel Technical Success

    Successful catheterization and stent placement in all intended target vessels.

    Measured: At procedure

  2. Procedural Technical Success

    All of the qualifying criteria are met (in the absence of surgical conversion or mortality, type I or type III endoleak, branch occlusion, or graft limb obstruction):

    • Successful access to the arterial system using remote arterial exposure, percutaneous technique, or open surgical conduits at index procedure.
    • Successful delivery and deployment of the aortic stent graft and all modular stent graft components at index procedure
    • Successful side branch catheterization and placement of bridging stents with restoration and maintenance of flow in all intended target vessels at final completion angiography
    • Absence of type I or type III endoleaks at final completion angiography that extends beyond 30 days by confirmatory imaging
    • Patency of all aortic modular stent graft components and intended side branch components at final completion angiography.

    Measured: at procedure

  3. Clinical Success

    Requires all of the following to be met:

    • Procedural Technical success
    • Absence of death from the initial procedure, secondary intervention, or aorta-related cause
    • Absence of persistent type I or type III endoleaks
    • Absence of aneurysm sac expansion > 5mm
    • Absence of device migration > 10mm
    • Absence of failure due to device integrity issues
    • Absence of aneurysm rupture
    • Absence of conversion to open surgical repair
    • Absence of permanent paraplegia
    • Note: defined as spinal cord deficit with inability to walk and not resolving at a future assessment
    • Absence of disabling stroke
    • Note: defined as stroke with one of the following: complete hemianopia, severe aphasia, visual or sensory extinction, or any weakness limiting sustained effort against gravity
    • Absence of new-onset dialysis following the initial operation

    Measured: through 5-year follow-up

  4. Major Adverse Events

    Any of the following events:

    • All-cause mortality
    • Myocardial infarction (MI): MI resulting in severe hemodynamic dysfunction necessitating resuscitation, cardiac arrest, or fatal outcome
    • Respiratory failure requiring prolonged (> 24 hours from anticipated) mechanical ventilation or reintubation
    • Renal function decline characterized by one or more of the following:
    • >50% reduction in baseline estimated glomerular filtration rate (eGFR); or,
    • New-onset dialysis
    • Bowel ischemia requiring surgical resection or not resolving with medical therapy
    • Permanent paraplegia
    • Major stroke.
    • Note: any stroke that is disabling or fatal

    Measured: through 5-year follow-up

  5. Freedom from Aneurysm-Related Mortality

    Freedom from all the following:

    • Any death that occurs within the first 30 days
    • any death that results from aneurysm rupture, aorta-related complications such as infection, occlusion, dissection, hematoma, or
    • any death that results from a complication of a secondary intervention

    Measured: through 5-year follow-up

  6. Freedom from Target Vessel Instability through 5-year follow-up

    Freedom from any death or rupture related to side branch complication (e.g., endoleaks, rupture); any branch occlusion; or any secondary intervention indicated to treat a branch-related complication, including endoleaks, disconnection, kink, stenosis, occlusion, or rupture

    Measured: through 5-year follow-up

  7. Primary Patency

    Uninterrupted patency with no occlusion or additional procedures performed intended to maintain patency of the stent or native target vessel.

    Note: Interventions intended to treat endoleaks or stent disconnection do not count as loss of primary patency.

    Measured: through 5-year follow-up

  8. Freedom from Reintervention

    Any repeated vascular or nonvascular procedure on the aortic endovascular stent graft, its branches, or any other stent graft placed in combination with these devices during the index procedure.

    Measured: through 5-year follow-up

  9. Survival

    Freedom from all-cause mortality

    Measured: through 5-year follow-up

  10. Aneurysm sac changes

    Aneurysm Enlargement: An increase in maximum aorta diameter of > 5mm in the region encompassed by the initial aneurysm as compared to baseline.

    Aneurysm Shrinkage: A decrease in aorta diameter of > 5-mm in the region encompassed by the initial aneurysm as compared to baseline.

    Stable Aneurysm: A ≤ 5 millimeter (mm) change in aorta diameter in the region encompassed by the initial aneurysm as compared to baseline.

    Measured: through 5-year follow-up

  11. Primary Assisted Patency

    Number of patients with endovascular intervention performed to maintain patency in the presence of a stenosis before occlusion

    Measured: through 5-year follow-up

  12. Secondary Patency

    Number of patients with endovascular restoration of patency after occlusion of the side branch, stent, or stent graft has already occurred.

    Measured: through 5-year follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Mar 2026
  2. Study startDec 2026 (estimated)
  3. Primary completionDec 2031 (estimated)
  4. Study completionDec 2035 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (estimated)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07480395
Sponsor's protocol ID
VSC 25-08
Acronym
ENVISION
Status last verified
Oct 2026
First submitted
13 Mar 2026
Last updated
23 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in